{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035670","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.805632+00:00","generated_at":"2026-06-21T03:40:49.205851+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biofrontera shareholders approve 94% increase in equity plan shares, elect director","bullets":["Shareholders approved amendment increasing authorized shares under 2021 Omnibus Incentive Plan from 2.75M to 5,339,800 (narrowly passed: 4.77M for, 4.74M against).","Loretta Wedge elected as Class I director for term expiring at 2025 annual meeting (7.49M for, 2.03M withheld, 2.93M broker non-votes).","Ratification of Grant Thornton LLP as independent auditor for FY2022 approved (10.27M for, 2.06M against, 127,393 abstain).","Amendment was previously approved by Board on Oct 20, 2022 and effective Dec 12, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035670","json":"https://secwatch.observer/filing/0001493152-22-035670.json","markdown":"https://secwatch.observer/filing/0001493152-22-035670.md","text":"https://secwatch.observer/filing/0001493152-22-035670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/0001493152-22-035670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:40:49.205851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0841eee173ae393e6dfc9c071fe17fe3a94023d4","claim":"Biofrontera Inc. shareholders approved Election of Loretta Wedge as Class I Director at the 2022-12-12 meeting.","evidence_excerpt":"1.Election of Loretta Wedge as Class I Director For Withheld Broker Non-Votes 7,486,331 2,034,869 2,933,188 As a result, Ms. Wedge was elected for a term expiring at the 2025 annual meeting of stockholders or until her earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/0001493152-22-035670-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-12"}],"fact_type":"shareholder_vote"},{"claim_id":"62dcf7eedcb683cc594492cf72725b214d757b8e","claim":"Biofrontera Inc. shareholders approved Ratification of Appointment of Independent Public Accounting Firm at the 2022-12-12 meeting.","evidence_excerpt":"3. Ratification of Appointment of Independent Public Accounting Firm For Against Abstain Broker Non-Votes 10,267,203 2,059,792 127,393 N/A As a result, the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/0001493152-22-035670-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-12"}],"fact_type":"shareholder_vote"},{"claim_id":"6dceedbcf7408585503958c3e64b26827bfd3660","claim":"Biofrontera Inc. shareholders approved Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the Plan at the 2022-12-12 meeting.","evidence_excerpt":"2.Approval of Amendment to Increase the Number of Shares of Common Stock Authorized for Issuance under the Plan For Against Abstain Broker Non-Votes 4,768,084 4,739,209 13,907 2,933,188 As a result, the Amendment was duly approved by the Company’s stockholders and effective as of December 12, 2022, the total number of shares authorized for issuance under the Plan was increased to 5,339,800 shares of stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315222035670/0001493152-22-035670-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}